Vitamin D and Polycystic Ovarian Syndrome (PCOS)

Last updated: February 17, 2025
Sponsor: Aga Khan University
Overall Status: Active - Recruiting

Phase

2

Condition

Infertility

Treatment

Vitamin D

Clinical Study ID

NCT03989778
124
  • Ages 18-36
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Primary Objectives:

To evaluate the efficacy of metformin and Vitamin D supplementation on serum insulin and serum androgen levels (Total testosterone, Steroid Hormone Binding Globulin, Free Androgen Index) levels compared metformin alone in infertile Poly cystic ovarian females of reproductive age group.

Secondary Objectives:

To measure change in endometrial thickness/number of follicles and follicular size by day 12 trans-vaginal ultrasound in the intervention group i.e. combination of metformin and vitamin D supplementation

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Females with age range 18- 36 years, from all ethnic background having primaryinfertility with diagnosis of PCOS when at least 2 of these 3 elements are present:hyperandrogenism, chronic anovulation and polycystic ovaries and Vitamin Ddeficiency serum levels < 25 nmol/L

Exclusion

Exclusion Criteria:

exclusion criteria at baseline will be excluded from the study

  • Females with secondary Infertility

  • Hypercalcemia (plasma calcium concentrations> 2.65 mmol/L)

  • Exclude women with Tuberculosis or other granulomatous disorders.

  • Women receiving vitamin D replacement, oral contraceptives, hormonal replacementtherapy, glucocorticoids, calcium supplementation, insulin-sensitizingdrugs(incretin mimetic drugs, thiazolidinedione, sulfonylurea), lipid-lowering drugsor other drugs affecting insulin sensitivity or serum androgens (e.g., niacin,corticosteroids, beta-blockers, calcium channel blockers, thiazide diuretics),anti-epileptics, anti-retroviral, cholestyramine, anti-fungal, statins, H2 blockers,immunosuppressants, chemotherapeutic agents, antimicrobials (Rifampicin, isoniazid,hydroqychloroquin) or any other drug modifying lipid metabolism in the previous 3months prior to study

  • Women with congenital adrenal hyperplasia, Cushing's syndrome, androgen-secretingtumors, type 2 diabetes mellitus, renal, hepatic or thyroid disorders,hyperparathyroidism, malabsorption syndromes, Chronic Kidney Disease Hepaticfailure, cystic fibrosis, vaginal bleeding of unknown etiology Women Those who hadBariatric surgery will also be excluded.

Study Design

Total Participants: 300
Treatment Group(s): 1
Primary Treatment: Vitamin D
Phase: 2
Study Start date:
February 01, 2023
Estimated Completion Date:
July 13, 2025

Study Description

Polycystic ovary syndrome (PCOS) as defined by "the presence of any two out of three criteria i.e. Oligo and/or anovulation, excess androgen activity and/or polycystic ovarian morphology on ultrasound", is a prevalent cause of female infertility. In the endocrine milieu of PCOS higher levels of insulin due to insulin resistance (IR) exert direct effects on the ovaries, release insulin-like growth factor 1 (IGF-1) from the liver and both then increase levels of testosterone. The resultant prevents the growth of ovarian follicles to acquire the required dimension for ovulation (i.e. > 10 mm) hence leading to anovulation and therefore subfertility. Vitamin D (VD) has found to be predominantly deficient in PCOS females, documented to cause IR giving rise to anovulatory cycles, hyperandrogenism and other significant features of PCOS. Therefore, we have hypothesized that treatment with VD in PCOS females can reduce IR, improve ovulation and signs of hyperandrogenism. Since Metformin is frequently prescribed for reducing IR and hence the treatment for anovulatory infertility in these females, we have planned to conduct an open label randomized control trial in PCOS infertile females who have vitamin D levels < than 25 ng/ml and are receiving Metformin therapy after ethical approval from Aga Khan University. The intervention group will receive VD Cholecalciferol (D2) 50,000 I.U once weekly for 12 weeks, followed by 50,000 I.U once every fortnight for 24 weeks with the Metformin treatment as prescribed by the physician whereas control group will receive Metformin treatment during the study period. We will compare change in number of dominant follicles (more than 10 mm) / endometrial thickness in both groups by Day 12 trans-vaginal ultrasound at the time of enrollment with scans done after 12 and 24 weeks. The other biochemical parameters [Total Testosterone, Steroid Hormone Binding Globulin, Free Androgen Index, Lipid Accumulation Product, Serum Insulin, Serum Triglycerides, Serum Calcium and Albumin] will be done at the time of recruitment in both the intervention and control groups and compared.

Connect with a study center

  • Dr Rehana Rehman

    Karachi, Sindh 74800
    Pakistan

    Active - Recruiting

  • Aga Khan University

    Karachi,
    Pakistan

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.